Clinical Trial

Rezafungin Prophylaxis in Liver Transplant

Enrolling by Invitation Phase 3
View on ClinicalTrials.gov →
Summary
This is an interventional study to evaluate the efficacy of rezafungin, a new echinocandin, for the prevention of invasive fungal infections (IFIs) after liver transplantation. Patients who receive rezafungin will be compared to a similar group of patients who underwent liver transplantation in the preceding two years for the incidence of IFIs.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-01-08; most recent amendment 2025-10-15.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-07-01
Trial Details
NCT Number NCT06774144
Lead Sponsor Fernanda P Silveira, MD, MS
Collaborators: Melinta Therapeutics
Conditions Liver Transplant Infection, Fungal Infection
Enrollment 385 participants
Start Date 2025-10-15
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-10-20